Characteristics | Linezolid therapy group | Control group | Total |
Subjects n | 33 | 32 | 65 |
Age years | 44 (18–64) | 43 (18–63) | 44 (18–64) |
Male sex | 22 (66.7) | 21 (65.6) | 43 (66.2) |
Body mass index kg·m−2 | 19.5 (12–30) | 19.6 (12–30) | 19.5 (12–30) |
With comorbidity | |||
Diabetes | 6 (18.2) | 6 (18.8) | 12 (18.5) |
Chronic obstructive pulmonary disease | 3 (9.1) | 4 (12.5) | 7 (10.8) |
Bronchiectasis | 8 (24.2) | 9 (28.1) | 17 (26.2) |
Tuberculous pleurisy | 6 (18.2) | 5 (15.6) | 11 (16.9) |
Respiratory failure¶ | 7 (21.2) | 6 (18.8) | 13 (20) |
Decreased albumin | 10 (30.3) | 9 (28.1) | 19 (29.2) |
Lung cavities | |||
Unilateral | 16 (48.5) | 15 (46.9) | 31 (47.7) |
Bilateral | 17 (51.5) | 17 (53.1) | 34 (52.3) |
Course of disease | |||
≥1 year <5 years before randomisation | 19 (57.6) | 18 (56.2) | 37 (56.9) |
≥5 years before randomisation | 14 (42.4) | 14 (43.8) | 28 (43.1) |
Previous treatment | |||
≥1 year <5 years before randomisation | 21 (66.7) | 22 (68.7) | 38 (67.7) |
≥5 years before randomisation | 11 (33.3) | 10 (31.3) | 21 (32.3) |
Susceptibility test results resistance | |||
Streptomycin | 30 (90.9) | 30 (93.8) | 60 (92.3) |
Isoniazid | 33 (100) | 32 (100) | 65 (100) |
Rifampin | 33 (100) | 32 (100) | 65 (100) |
Ethambutol | 29 (87.9) | 30 (93.8) | 59 (90.8) |
Ofloxacin | 33 (100) | 32 (100) | 65 (100) |
Amikacin | 26 (78.8) | 25 (78.1) | 51 (78.5) |
Capreomycin | 25 (75.8) | 25 (78.1) | 50 (76.9) |
Background regimen | |||
Prothionamide, pyrazinamide, moxifloxacin or gatifloxacin or levofloxacin, para-aminosalicylic acid | 33 (100) | 32 (100) | 65 (100) |
Capreomycin or amikacin | 18 (54.5) | 17 (53.1) | 35 (53.8) |
Clofazamine | 22 (66.7) | 20 (59.4) | 42 (64.6) |
Clarithromycin | 18 (54.5) | 19 (51.5) | 37 (56.9) |
Data are presented as n (%) or mean (minimum–maximum), unless otherwise stated. #: there were no significant between-group differences; ¶: respiratory failure was defined as arterial oxygen tension lower than 60 mmHg by arterial blood gas analysis.